octreotide
Commercial- Indications
- Acromegaly
Company intelligence / Profile preview
Chiasma
Waltham, Massachusetts, United Stateschiasmapharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~18
- Development stage
- Commercial
01
Overview
Successfully completed Phase 3 clinical trials for octreotide capsules (Mycapssa®) for acromegaly treatment. Mycapssa was launched in the US in August 2020 as the first oral somatostatin analog for long-term maintenance treatment of acromegaly[6][9].
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Oral formulations of injectable therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Chiasma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chiasma.